Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma

NCT07201415 | Active Not Recruiting

• 1 other identifier: 20250904
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

To explore the efficacy and safety of minimally invasive suprachoroidal drainage for the treatment of advanced neovascular glaucoma

Conditions

Neovascular Glaucoma

Keywords

Neovascular glaucoma; Retinal Vein Occlusion; Diabetic Retinopathy; Treatment

Outcome Measures

Primary Outcomes (4)

• Ocular biological parameters

  intraocular pressure

  1 day, 1 week, 1 month, 3 months, and 6 months after surgery

• Ocular biological parameters

  visual acuity

  1 day, 1 week, 1 month, 3 months, and 6 months after surgery

• Surgical outcome measures

  use of intraocular pressure lowering drugs

  1 day, 1 week, 1 month, 3 months, and 6 months after surgery

• The success rate of surgery was evaluated according to the specific value of intraocular pressure after surgery

  Complete success was defined as IOP within the normal range with no drug dependence, conditional success was defined as IOP within the normal range with drug dependence, and failure was defined as the rest

  1 day, 1 week, 1 month, 3 months, and 6 months after surgery

Secondary Outcomes (2)

• The effective rate of surgery was evaluated according to the amplitude of IOP reduction after surgery and the change in the number of IOP-lowering drugs

  1 day, 1 week, 1 month, 3 months, and 6 months after surgery

• Surgical outcome measures

  1 day, 1 week, 1 month, 3 months, and 6 months after surgery

Study Arms (1)

Surgical Treatment Group

EXPERIMENTAL

The patient will undergo a minimally invasive suprachoroidal drainage procedure

Procedure: minimally invasive suprachoroidal drainage

Interventions

minimally invasive suprachoroidal drainage PROCEDURE

minimally invasive suprachoroidal drainage

Surgical Treatment Group

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Advanced (angle-closure) neovascular glaucoma with poorly controlled intraocular pressure (IOP \> 21mmHg) after medical or surgical treatment

You may not qualify if:

• Various other types of glaucoma (including primary open-angle glaucoma, primary open-closed glaucoma, normal tension glaucoma, juvenile glaucoma, congenital glaucoma, other special types of glaucoma, etc.)
• Eye infection within two weeks before surgery
• Non-glaucomatous intraocular diseases that affect intraocular pressure (choroidal hemorrhage or detachment, retinal detachment, lens subluxation, thyroid eye disease, clinically significant macular edema, eye tumors, etc.)
• Visual acuity of non-study eyes \< 0.05
• Congenital or acquired factors lead to ciliary body anatomical abnormalities

Sponsors & Collaborators

• Zhongnan Hospital: lead

Study Sites (1)

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

Location

MeSH Terms

Conditions

Glaucoma, Neovascular; Retinal Vein Occlusion; Diabetic Retinopathy

Condition Hierarchy (Ancestors)

Glaucoma; Ocular Hypertension; Eye Diseases; Retinal Diseases; Venous Thrombosis; Thrombosis; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Diabetic Angiopathies; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 10, 2025
• First Posted: October 1, 2025
• Study Start: January 1, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): March 1, 2027
• Last Updated: October 1, 2025

Record last verified: 2025-09

Locations

CN (1)